Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PD-1 inhibitor + pegaspargase + gemcitabine + oxaliplatin
- Development stage
- Unknown
- Lead developer
- Wei Xu
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
PD-1 inhibitor + pegaspargase + gemcitabine + oxaliplatin is a combination chemo-immunotherapy regimen being evaluated for the treatment of extranodal natural killer/T-cell lymphoma (ENKTL). The regimen consists of the P-GemOx chemotherapy backbone—comprising pegaspargase (an asparagine-depleting enzyme), gemcitabine (a nucleoside analog), and oxaliplatin (a platinum-based alkylating agent)—combined with a programmed death-1 (PD-1) inhibitor. This therapeutic approach aims to leverage the direct cytotoxic effects of chemotherapy alongside the immune-enhancing properties of checkpoint inhibition to overcome the aggressive nature of ENKTL. It is currently being studied in Phase 2 clinical trials, such as those led by investigator Wei Xu, as a first-line treatment for advanced or non-nasal subtypes of the disease.
- Other names
- P-GemOx + PD-1 inhibitorPD-1 inhibitor plus P-GemOxPD1 inhibitor plus P-GemOxPD 1 inhibitor plus P-GemOxPD-1 inhibitor + pegaspargase + gemcitabine + oxaliplatin
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)DNARNR (Ribonucleotide reductase)
Beyond the preview
Go deeper on PD-1 inhibitor + pegaspargase + gemcitabine + oxaliplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PD-1 inhibitor + pegaspargase + gemcitabine + oxaliplatin.